J13231 - Psychiatry & Behavioral Neurobiology

Mentor: Dr. Kazutoshi Nakazawa, Associate Professor, Department of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham, Birmingham, AL.  Email:  nakazawk@uab.edu


The Department of Psychiatry and Behavioral Neurobiology at the University of Alabama at Birmingham is seeking a highly motivated postdoctoral research fellow
with expertise in patch-clamp electrophysiology, to join multidisciplinary team studying pathophysiology of major neuropsychiatric disorders. Prior experience and publications on patch-clamp analysis of ion channels, preferably in cortical or hippocampal inter neurons, are essential. Experience with both voltage-clamp and current-clamp analysis is desirable. Superb opportunity to work collaboratively with cell and molecular biologists, in vivo physiologists, etc.


Candidates with a PhD or MD degree and experience in the above mentioned disciplines should apply with a CV, statement of research interest, and a list of three references to:Kazu Nakazawa, MD, PhD, electronically to e-mail: nakazawk@uab.edu. Equal Opportunity/Affirmative Action Employer.

 

 

 

 

 

 

UAB News

  • Mixed-media, design and sculptural works by Department of Art and Art History students Rob Clifton, Alejandra Garbutt and Nathan Truitt will be on display Dec. 1-13.Rob Clifton: "Idealized Serpentine Forms," 2014; paper, newspaper, canvas, acrylic, wheat paste, cardboard, masonite, string, space & light; site-specific installation, dimensions variableWorks by three graduating students from the University of Alabama at Birmingham’s Department of Art and Art History will be on exhibition Dec. 1-13, in the College of Arts...

  • The manufacturer of a new medication for Rett syndrome studied at UAB is encouraged by the drug’s performance.A recently concluded study of an experimental drug for Rett syndrome showed promising results, according to the drug’s manufacturer, Neuren Pharmaceuticals of Melbourne, Australia. The University of Alabama at Birmingham was one of three study sites for the drug, known as NNZ-2566. Neuren announced Nov. 12 that the Phase II study had achieved its primary endpoint as two dose...